| Literature DB >> 30305667 |
Rodrigo Carvalho1, Aline Vaz2, Felipe Luiz Pereira2, Fernanda Dorella2, Eric Aguiar3, Jean-Marc Chatel4, Luis Bermudez4, Philippe Langella4, Gabriel Fernandes5, Henrique Figueiredo2, Aristóteles Goes-Neto2, Vasco Azevedo2.
Abstract
Mucositis is an inflammatory condition of the gut, caused by an adverse effect of chemotherapy drugs, such as 5-fluorouracil (5-FU). In an attempt to develop alternative treatments for the disease, several research groups have proposed the use of probiotics, in particular, Lactic Acid Bacteria (LAB). In this context, the use of recombinant LAB, for delivering anti-inflammatory compounds has also been explored. In previous work, we demonstrated that either Lactococcus lactis NZ9000 or a recombinant strain expressing an antimicrobial peptide involved in human gut homeostasis, the Pancreatitis-associated Protein (PAP), could ameliorate 5-FU-induced mucositis in mice. However, the impact of these strains on the gut microbiota still needs to be elucidated. Therefore, in the present study, we aimed to characterize the effects of both Lactococci strains in the gut microbiome of mice through a 16 S rRNA gene sequencing metagenomic approach. Our data show 5-FU caused a significant decrease in protective bacteria and increase of several bacteria associated with pro-inflammatory traits. The Lactococci strains were shown to reduce several potential opportunistic microbes, while PAP delivery was able to suppress the growth of Enterobacteriaceae during inflammation. We conclude the strain secreting antimicrobial PAP was more effective in the control of 5-FU-dysbiosis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30305667 PMCID: PMC6180057 DOI: 10.1038/s41598-018-33469-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Phylum relative abundance in stool among the groups.
Figure 2Microbial richness of the fecal microbiota among the groups. LL group showed an increase in richness when compared to Naïve (P = 0.014), LL5FU (P = 0.022) and PAP5FU (P = 0.028). Bonferroni, P-value <0,05.
Figure 3Diversity analysis of fecal microbiota among the groups. There was no significant statistical variation. Bonferroni, P-value <0,05.
Figure 4Microbial evenness of the fecal microbiota among the groups. There was no significant statistical variation. Bonferroni, P-value <0,05.
Significant differences in microbial community among the groups using the multiple response permutation process (MRPP). The superior part of the table corresponds to the A-value and the inferior part to the P-value.
| Naive | LL | PAP | 5FU | LL5FU | PAP5FU | |
|---|---|---|---|---|---|---|
| Naive | 0.029 | −0.007 | 0.087 | 0.075 | 0.077 | |
| LL | 0.103 | 0.012 | 0.122 | 0.038 | 0.011 | |
| PAP | 0.517 | 0.229 | 0.131 | 0.068 | 0.063 | |
| 5FU | 0.025 | 0.054 | ||||
| LL5FU | 0.159 | −0.031 | ||||
| PAP5FU | 0.245 | 0.986 |
The A-value describes within-group homogeneity, compared to the random expectation. The P-values indicated the significant differences at the levels of P < 0.05.
Significant differences in microbial community among the groups using ANOSIM. The superior part of the table corresponds to the R-value and the inferior part to the P-value.
| Naive | LL | PAP | 5FU | LL5FU | PAP5FU | |
|---|---|---|---|---|---|---|
| Naive | 0.069 | − 0.015 | 0.193 | 0.184 | 0.182 | |
| LL | 0.073 | 0.006 | 0.272 | 0.099 | 0.029 | |
| PAP | 0.562 | 0.331 | 0.244 | 0.141 | 0.106 | |
| 5FU | 0.074 | 0.109 | ||||
| LL5FU | 0.095 | −0.057 | ||||
| PAP5FU | 0.185 | 0.063 | 0.954 |
The P-values indicated the significant differences at the levels of P < 0.05.
Figure 5Significant changes of OTU proportion among the groups. Kruskall Wallis comparison. P-value <0,05.